Collect Product
Product Details
Source
Chimeric Biotinylated Monoclonal Anti-TNF-alpha Antibody, human IgG1 (16H5) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to human IgG1 constant domains.
Antibody Type
Recombinant Monoclonal
Clone
16H5
Isotype
Human IgG1, Kappa
Host Species
Mouse
Reactivity
Human
Immunogen
Human TNF-alpha Protein is expressed from human 293 cells
Conjugate
Biotinylated
Specificity
This product is a specific antibody specifically reacts with TNF-alpha.
Purification
Protein A purified.
Aggregation
Less than 10%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Bioactivity-ELISA
Immobilized Human TNF-alpha Protein, His Tag (Cat. No. TNA-H5228) at 2 μg/mL (100 μL/well) can bind Biotinylated Monoclonal Anti-TNF-alpha Antibody, human IgG1 (16H5) (Cat. No. TNA-BLM494) with a linear range of 0.20-3.13 ng/mL (QC tested).
Protocol
Immobilized Monoclonal Anti-TNF-alpha Antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) at 2 μg/mL, add increasing concentrations of Human TNF-alpha Protein, His Tag (Cat. No. TNA-H5228), and then add Biotinylated Monoclonal Anti-TNF-alpha Antibody, human IgG1 (16H5) (Cat. No. TNA-BLM494) at 0.25 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.02 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Biotinylated Monoclonal Anti-TNF-alpha Antibody, human IgG1 (16H5) (Cat. No. TNA-BLM494) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNF-alpha, His Tag (Cat. No. TNA-H5228) with an affinity constant of 75.9 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Biotinylated Monoclonal Anti-TNF-alpha Antibody, human IgG1 (16H5) (Cat. No. TNA-BLM494) on Protein A Biosensor, can bind Human TNF-alpha, His Tag (Cat. No. TNA-H5228) with an affinity constant of 2.13 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Biotinylated Monoclonal Anti-TNF-alpha Antibody, human IgG1 (16H5) (Cat. No. TNA-BLM494) on Protein A Biosensor, can bind Human TNF-alpha, premium grade (Cat. No. TNA-H4211) with an affinity constant of 3.16 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
User Reviews Publish Comment
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Tumor necrosis factor α
- Category：
- Listed Drugs Count：
68 Details
- Clinical Drugs Count：
74 Details
- Highest R&D Stage：
Approved
Contact Us
Drug Candidate Licensing
